Dermatology
Semaphorin 3F prohibits melanoma metastasis
Published in Gene Therapy Weekly, January 27th, 2005
According to recent research from the United States, "melanoma is the most lethal skin cancer. Most deaths from melanoma result from metastases. Semaphorins have been shown to inhibit neuronal and endothelial cell migration, but the effects of semaphorins on tumor metastasis have not been documented."
"We found that semaphorin 3F (SEMA3F) was markedly down-regulated in highly metastatic human cell lines in vitro and in vivo, which suggested that it may be a metastasis inhibitor. Metastatic human melanoma cells were transfected with SEMA3F and implanted into mice; the resultant tumors did not metastasize,"...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-01-27)
More Articles from Gene Therapy Weekly
- Assisted Reproduction
Growth differentiation factor gene fragments treat porcine ovarian dysfunction - Cerebrovascular Disease
Homeobox D3 gene delivery initiates cerebral angiogenesis in mice - Gene Transfer
Jet injection and electroporation deliver plasmids to large muscles - Gene Transfer
Nucleotides targeting anti-apoptosis protein bind to erythroleukemia cells - Neurodegeneration
Beta-synuclein gene transfer protects mice from nervous system degeneration - Acute Myelogenous Leukemia
Clinical outcome not affected in pediatric AML patients with PTPN11 mutations - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
